Nuveen’s AN2 Therapeutics ANTX Stock Holding History

Nuveen’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,546	Closed	-$153K	–	3210
2023 Q1	$153K	Buy	15,546 +481	+3%	+$5.35K	﹤0.01%	3020
2022 Q4	$144K	Buy	+15,065	New	+$202K	﹤0.01%	3077

Other funds holding ANTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Nuveen's ANTX Position: Q2 2023 in Review

Nuveen sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 15,546 shares — an estimated $153K sold.

Nuveen first reported a position in ANTX in Q4 2022 and held it in 2 quarters. The position peaked at $153K in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

Nuveen reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
Nuveen sold 15,546 AN2 Therapeutics shares in Q2 2023, an estimated $153K.
Nuveen first reported a position in AN2 Therapeutics in Q4 2022 and held it in 2 quarters.
Nuveen's AN2 Therapeutics position peaked at $153K in Q1 2023.
31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on Nuveen's 13F filing for Q2 2023, filed 14 Aug 2023.